Keros Therapeutics /zigman2/quotes/217766474/composite KROS -4.98% has set terms of its initial public offering, in which it expects to raise up to $80 million, and be valued at about $291 million. The biopharmaceutical company, which is developing treatments for hematological and musculoskeletal disorders, if offering 5 million shares for sale with the IPO expected to price between $14 and $16 a share. The stock is expected to be listed on the Nasdaq exchange under the ticker symbol "KROS." Jefferies, SVB Leerink and Piper Sandler are the joint book-running managers. The company recorded a net loss of $14.1 million on revenue of $10 million in 2019 after a loss of $2.3 million on revenue of $10 million in 2018. Keros is looking to go public at a time that the Renaissance IPO ETF /zigman2/quotes/207665280/composite IPO +0.11% has lost 15.3% over the past three months and the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.18% has dropped 20.0%.